What's new

Clinical human trials begin for COVID-19 vaccine in China

.
Beijing & Tianjin provide aerosolized adenovirus vector vaccine as booster shots starting Thu, as COVID flare-ups caused by Omicron variants have been reported across China, with new infections in Beijing rising.
https://globaltimes.cn/page/202211/1279178.shtml

@butantanoficial will deliver another 1 million doses of SINOVAC COVID-19 vaccine CoronaVac to the Brazilian Ministry of Health, mainly for immunization of children 3 to 5 years old.#COVID19 #coronavac

Cansino [SHA: 688185] rose 13.3% as of today’s lunch break after the Chinese vaccine maker said its inhaled #COVID19 vaccine was approved for emergency use by Morocco's health ministry. The firm’s Hong Kong-listed shares [HKG: 6185] soared nearly 18%.
 
. .
Screenshot_20221124_095550_com.android.chrome.jpg


12000 died from Covid in US on the 11 Nov. 90'000 died from Covid since the much ridiculed Shanghai lockdowns began.
 
. . .
.
You mean like this?

Vaccines work. Masking works. I survived covid. So did a dozen others I know. Granted the folks are in 20-60 year old age group. One of them is in high risk category
 
.
Vaccines work. Masking works. I survived covid. So did a dozen others I know. Granted the folks are in 20-60 year old age group. One of them is in high risk category
Depends on age group, Pfizer vaccine is practically useless against the new ones.
 
. . .
A new COVID-19 vaccine, SCTV01C (a bivalent recombinant Trimeric S protein vaccine), developed by the SinoCellTech in Beijing has been approved for emergency use in China. It is reportedly the first vaccine targeting Alpha, Beta variants rather than the original virus in China.




1670300422278.png





Sinocelltech, Clover Soar as Vaccine Makers’ #COVID19 Jabs Are Approved for Use in China https://bit.ly/3h07VyR
 
Last edited:
.
Volunteers receive China's first COVID-19 vaccine candidate from insect cells
By Cao Siqi Source: Global Times Published: 2020/8/31 19:18:40

bb1b44b5-fd33-4c87-8017-4ae7217d360c.jpeg
Volunteers receive China's first COVID-19 vaccine candidate from insect cells developed by the State Key Laboratory of Biological Therapy of Sichuan University-affiliated West China Hospital. Photo: Courtesy of the hospital

China's first recombinant protein COVID-19 vaccine made from insect cells was recently injected in volunteers, who said they felt good and have had no adverse reactions so far, the Global Times learned from the vaccine developer on Monday.

Developed by the State Key Laboratory of Biological Therapy of Sichuan University-affiliated West China Hospital, the vaccine uses insect cells to multiply in the culture medium, and introduces the gene of COVID-19 to insect cells, which means the cell can be used to produce high-quality recombinant vaccine proteins and purify them for refinement.

The vaccine was injected in several volunteers on Saturday morning, according to a hospital statement sent to the Global Times.

Academician Wei Yuquan, the director of the lab, said the vaccine was approved for clinical trials by the National Medical Products Administration on August 21 after being tested on monkeys and other animals. It was found to have a good protective effect against COVID-19 infection, with no obvious side effects.

It is easy to mass-produce the vaccine, Wei said.

So far, four types of coronavirus vaccines in China have started Phase III clinical trials, and some will be injected in volunteers in early September.

dde3e0f5-1adb-4afc-80fb-4d7368f0a875.jpeg
Volunteers receive China's first COVID-19 vaccine candidate from insect cells developed by the State Key Laboratory of Biological Therapy of Sichuan University-affiliated West China Hospital. Photo: Courtesy of the hospital

The Phase III clinical trials determine whether the vaccine would be approved. It will verify the vaccine's safety and effectiveness, which requires tens of thousands of samples.

Media reported that the phase 3 clinical trials are expected to achieve preliminary results as early as of November.

Results of Phase I and Phase II show several vaccines have been safe and effective.

A document published by the National Food and Drug Administration on August 15 said a novel coronavirus vaccine should be able to provide protection for at least six months.

There are five main technologies for the development of COVID-19 vaccine in China - inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine, nucleic acid vaccine based on mRNA and DNA, and attenuated influenza virus vector vaccine.

Developers around the world are racing against the clock with 170 vaccine candidates. Among those candidates, four from China, two from the US, and one from the UK have entered the last phase. Russia's vaccine, Sputnik V, has recently been under the spotlight after the country announced on August 11 that it had become the first in the world to approve a coronavirus vaccine for widespread use.

3ace6a76-7c81-4f14-bc6b-33ff013ed37f.jpeg
The State Key Laboratory of Biological Therapy of Sichuan University-affiliated West China Hospital starts research on COVID-19 vaccine made from insect cells. Photo: Courtesy of the hospital
#Coviccine developed by WestVac Biopharma and West China Hospital of Sichuan University is the first insect cell-expressed Recombinant #COVID19 vaccine recently approved for emergency use in #China. http://westvacpharma.com/detail/77

A total of 4 new vaccines have received EUA in #China over the past few days. This includes 3 recombinant protein vaccines developed by Sinocelltech Group, Clover Biopharmaceutical and WestVac Biopharma/West China Hospital of Sichuan University...

... plus 1 nasal spray vaccine jointly developed by HKU, Xiamen University and Beijing Wantai Biological Pharmacy. The Chinese government has yet to confirm their use within the #COVID19 vaccine schedule, whether they'll be used as a booster dose option or a potential 4th shot.
 
.
Recbio Soars After Chinese Vaccine Maker Says Its Upcoming #COVID19 Jab Is Better Than Pfizer’s
https://bit.ly/3YlnMJ4
 
. .

Country Latest Posts

Back
Top Bottom